Vivus's top shareholder proposes former AstraZeneca exec as CEO
July 2 (Reuters) - Vivus Inc's largest shareholder First Manhattan Co said it proposed a former senior executive of AstraZeneca Plc as chief executive of the obesity drug maker, a move that could swing shareholder support for the activist investor's board slate ahead of a proxy vote.
Anthony Zook, who was executive vice-president for global commercial operations at AstraZeneca until February, helped in launch some of the British drug giant's biggest products, including the blockbuster heartburn drug Nexium and cholesterol medicine Crestor.
First Manhattan, owner of 9.9 percent of Vivus shares, has repeatedly criticized the drug maker for mishandling the launch of its obesity drug Qsymia.
First Manhattan put forth a slate of nine candidates that it hopes will win seats on the Vivus board at the shareholder meeting on July 15.
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters press on |
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
- Singapore hit by rare outbreak of rioting, 27 arrested |
- Venezuela's Maduro to raise pressure on business after local vote